Liquidia highlights strong YUTREPIA launch and growth plans

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAn update from Liquidia Technologies ( (LQDA) ) is now available. On January 9, 2026, Liquidia Corporation reported preliminary, unaudited 2025 financial and operating results showing a strong commercial debut for YUTREPIA, with estimated net product sales of about $90.1 million in the fourth quarter and $148.3 million for the full year, fueled by 74% quarter-over-quarter sales growth, more than $30 million in positive fourth-quarter cash flow, and cash and equivalents of roughly $190.7 million at year-end. Since regulatory approval on May 23, 2025, the company has received over 2,800 unique prescriptions, initiated treatment for more than 2,200 patients with an 85% conversion rate and roughly 750 prescribers by December 31, 2025, and now plans to expand its field sales team and invest in an extensive 2026 clinical program to further differentiate YUTREPIA and L606 across PAH, PH-ILD, fibrotic lung diseases and related indications, reinforcing its competitive positioning in the inhaled prostacyclin market and signaling continued growth ambitions in pulmonary hypertension and associated conditions. The most recent analyst rating on (LQDA) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page. Spark’s Take on LQDA Stock According to Spark, TipRanks’ AI Analyst, LQDA is a Neutral. Liquidia Technologies’ overall stock score is driven by strong technical momentum and positive strategic developments, such as the successful launch of YUTREPIA and a new licensing deal. However, financial performance remains a concern due to high leverage and negative profitability, which weighs heavily on the score. Valuation metrics are also weak, reflecting ongoing financial challenges. To see Spark’s full report on LQDA stock, click here. More about Liquidia Technologies Liquidia Corporation is a U.S.-based biopharmaceutical company focused on treating challenging respiratory and vascular diseases, notably pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead approved product is YUTREPIA, an inhaled dry-powder formulation of treprostinil engineered with the company’s proprietary PRINT technology, and it is also developing L606, an extended-release liposomal treprostinil inhalation suspension, alongside a generic treprostinil injection marketed in partnership with Sandoz. Average Trading Volume: 1,877,379 Technical Sentiment Signal: Buy Current Market Cap: $2.7B For an in-depth examination of LQDA stock, go to TipRanks’ Overview page.